Business UpdateJul 10, 2026, 04:02 PM
Clearmind Medicine Responds to US Admin RFI for Addiction Treatment
AI Summary
Clearmind Medicine Inc. announced its formal response to the U.S. Department of Health and Human Services (HHS) Request for Information (RFI) regarding addiction treatment innovations. The company proposed an innovative model for Alcohol Use Disorder (AUD) treatment, highlighting its proprietary MEAI-based candidate CMND-100 as a non-hallucinogenic neuroplastogen. This submission is part of the "Great American Recovery Initiative" and aims to position CMND-100 as a scalable, at-home solution for the millions affected by AUD.
Key Highlights
- Clearmind Medicine responded to a U.S. Department of Health and Human Services (HHS) Request for Information (RFI).
- The RFI is about addiction treatment innovations as part of the "Great American Recovery Initiative".
- Clearmind proposed an innovative model for inexpensive, scalable, and clinically effective treatment for Alcohol Use Disorder (AUD).
- Highlighted its proprietary MEAI-based candidate CMND-100, a non-hallucinogenic neuroplastogen for AUD and binge behaviors.
- Emphasized that AUD affects approximately 10% of the U.S. population, with only 1 in 10 receiving treatment.
- CMND-100 is positioned as a scalable, at-home solution with low abuse potential, engaging neural pathways for moderation and long-term recovery.
- The company aims to offer safe, reproducible delivery in community-based, rural, and underserved settings.
Price Impact
More from CMND